UCB (OTCMKTS:UCBJY) Shares Gap Down After Analyst Downgrade

Shares of UCB SA (OTCMKTS:UCBJY) gapped down prior to trading on Monday after Barclays downgraded the stock from a strong-buy rating to a hold rating. The stock had previously closed at $158.72, but opened at $150.53. UCB shares last traded at $151.3950, with a volume of 26,509 shares traded.

A number of other equities research analysts also recently issued reports on UCBJY. Wolfe Research raised UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, UCB has an average rating of “Moderate Buy”.

UCB Trading Down 0.6%

The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average of $145.35 and a 200-day moving average of $147.44.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.